rituximab
Showing 26 - 50 of 1,252
Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)
Recruiting
- Follicular Lymphoma
- +2 more
- Rituximab
- Copanlisib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Trial in Rozzano (Rituximab)
Active, not recruiting
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Rituximab
-
Rozzano, Milano, ItalyIstituto Clinico Humanitas
May 17, 2023
Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)
Active, not recruiting
- Post-transplant Lymphoproliferative Disorder
- Rituximab
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Jan 16, 2023
Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Oct 31, 2022
Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 26, 2022
Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)
Not yet recruiting
- Large B-cell Lymphoma
- B-cell Lymphoma
- Magrolimab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2023
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS Trial in Amsterdam
Recruiting
- Multiple Sclerosis
- +5 more
- Rituximab
-
Amsterdam, NetherlandsAmsterdam UMC, location VUmc
Apr 17, 2023
Steroid-Sensitive Nephrotic Syndrome Trial in Shanghai (Rituximab, Corticosteroid)
Not yet recruiting
- Steroid-Sensitive Nephrotic Syndrome
- Rituximab
- Corticosteroid
-
Shanghai, Shanghai, China
- +2 more
May 6, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia
- Nemtabrutinib
- +7 more
- (no location specified)
Nov 30, 2022
APS Secondary to SLE
Recruiting
- Antiphospholipid Syndrome
- Telitacicept
- +5 more
-
Jinan, Shandong, ChinaQilu Hospital
Nov 30, 2022
Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)
Not yet recruiting
- Large B-Cell Lymphoma
- Glofitamab
- +5 more
-
Xi'an, ChinaFirst Affiliated Hospital of Medical College of Xi'an Jiaotong U
Sep 14, 2023
Rheumatoid Arthritis Trial in Belgium (Rituximab)
Not yet recruiting
- Rheumatoid Arthritis
- Rituximab
-
Merksem, Antwerpen, Belgium
- +6 more
Aug 17, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Pharmacological Action Trial (Rituximab, Dexamethasone)
Not yet recruiting
- Pharmacological Action
- Rituximab
- Dexamethasone
- (no location specified)
Sep 22, 2022
Schizophrenia Spectrum and Other Psychotic Disorders Trial in Örebro (Rituximab)
Not yet recruiting
- Schizophrenia Spectrum and Other Psychotic Disorders
- Rituximab
-
Örebro, SwedenÖrebro university hospital
Nov 21, 2022
Hairy Cell Leukemia Trial run by the NCI (Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience)
Active, not recruiting
- Hairy Cell Leukemia
- Moxetumomab Pasudotox-tdfk
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Rituximab in Children With Blood Diseases
Not yet recruiting
- Rituximab
- +2 more
- Rituximab
- Rituximab (once a week)
- (no location specified)
Apr 8, 2022
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
Lymphoma Trial in Houston (Rituximab, Lenalidomide, Valemetostat)
Not yet recruiting
- Lymphoma
- Rituximab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 4, 2023
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)
Active, not recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Ruijin Hospital
Dec 1, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023